Sara Rosenblum1, Sonya Meyer1, Netta Gemerman1,2, Lilya Mentzer2, Ariella Richardson3, Simon Israeli-Korn2,4,5, Vered Livneh2,4, Tsvia Fay Karmon2,4, Tal Nevo2, Gilad Yahalom2,4,5, Sharon Hassin-Baer2,4,5. 1. The Laboratory of Complex Human Activity and Participation Department of Occupational Therapy, Faculty of Social Welfare & Health Sciences University of Haifa Haifa Israel. 2. Movement Disorders Institute Sheba Medical Center Ramat-Gan Israel. 3. Department of Industrial Engineering Lev Academic Center Jerusalem Israel. 4. Department of Neurology Sheba Medical Center Ramat-Gan Israel. 5. Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel.
Abstract
BACKGROUND: Administering an abbreviated global cognitive test, such as the Montreal Cognitive Assessment (MoCA), is necessary for the recommended first-level diagnostic criteria for mild cognitive impairment (MCI) in Parkinson's disease (PD). Level II requires administering cognitive functioning neuropsychological tests. The MoCA's suitability for identifying PD-MCI is questionable and, despite the importance of cognitive deficits reflected through daily functioning in identifying PD-MCI, knowledge about it is scarce. OBJECTIVES: To explore neuropsychological test scores of patients with PD who were categorized based on their MoCA scores and to analyze correlations between this categorization and patients' self-reports about daily functional-related cognitive abilities. METHODS: A total of 78 patients aged 42 to 78 years participated: 46 with low MoCA scores (22-25) and 32 with high MoCA scores (26-30). Medical assessments and level II neuropsychological assessment tools were administered along with standardized self-report questionnaires about daily functioning that reflects patients' cognitive abilities. RESULTS: A high percentage of the low MoCA group obtained neuropsychological test scores within the normal range; a notable number in the high MoCA group were identified with MCI-level scores on various neuropsychological tests. Suspected PD-MCI according to the level I criteria did not correspond well with the level II criteria. Positive correlations were found among the 3 self-report questionnaires. CONCLUSIONS: These results support the ongoing discussion of the complexity of capturing PD-MCI. Considering the neuropsychological tests results, assessments that reflect cognitive encounters in real life daily confrontations are warranted among people diagnosed with PD who are at risk for cognitive decline.
BACKGROUND: Administering an abbreviated global cognitive test, such as the Montreal Cognitive Assessment (MoCA), is necessary for the recommended first-level diagnostic criteria for mild cognitive impairment (MCI) in Parkinson's disease (PD). Level II requires administering cognitive functioning neuropsychological tests. The MoCA's suitability for identifying PD-MCI is questionable and, despite the importance of cognitive deficits reflected through daily functioning in identifying PD-MCI, knowledge about it is scarce. OBJECTIVES: To explore neuropsychological test scores of patients with PD who were categorized based on their MoCA scores and to analyze correlations between this categorization and patients' self-reports about daily functional-related cognitive abilities. METHODS: A total of 78 patients aged 42 to 78 years participated: 46 with low MoCA scores (22-25) and 32 with high MoCA scores (26-30). Medical assessments and level II neuropsychological assessment tools were administered along with standardized self-report questionnaires about daily functioning that reflects patients' cognitive abilities. RESULTS: A high percentage of the low MoCA group obtained neuropsychological test scores within the normal range; a notable number in the high MoCA group were identified with MCI-level scores on various neuropsychological tests. Suspected PD-MCI according to the level I criteria did not correspond well with the level II criteria. Positive correlations were found among the 3 self-report questionnaires. CONCLUSIONS: These results support the ongoing discussion of the complexity of capturing PD-MCI. Considering the neuropsychological tests results, assessments that reflect cognitive encounters in real life daily confrontations are warranted among people diagnosed with PD who are at risk for cognitive decline.
Authors: Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre Journal: Mov Disord Date: 2012-01-24 Impact factor: 10.338
Authors: Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins Journal: Mov Disord Date: 2013-10-09 Impact factor: 10.338
Authors: Paolo Barone; Dag Aarsland; David Burn; Murat Emre; Jaime Kulisevsky; Daniel Weintraub Journal: Mov Disord Date: 2011-08-24 Impact factor: 10.338
Authors: Emily C Edmonds; Lisa Delano-Wood; Amy J Jak; Douglas R Galasko; David P Salmon; Mark W Bondi Journal: J Alzheimers Dis Date: 2016-03-31 Impact factor: 4.472
Authors: Matej Skorvanek; Jennifer G Goldman; Marjan Jahanshahi; Connie Marras; Irena Rektorova; Ben Schmand; Erik van Duijn; Christopher G Goetz; Daniel Weintraub; Glenn T Stebbins; Pablo Martinez-Martin Journal: Mov Disord Date: 2017-11-23 Impact factor: 10.338
Authors: Roy P C Kessels; Nathalie R de Vent; Carolien J W H Bruijnen; Michelle G Jansen; Jos F M de Jonghe; Boukje A G Dijkstra; Joukje M Oosterman Journal: J Clin Med Date: 2022-07-13 Impact factor: 4.964